Caldan Therapeutics
closedDevelops innovative therapeutics targeting Type 2 Diabetes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
£1.5m | Seed | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (13574800 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (11995433 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Caldan Therapeutics is a pioneering biotech startup focused on discovering new treatments for metabolic diseases, such as Type 2 Diabetes, and other conditions like non-alcoholic steatohepatitis (NASH) and inflammatory diseases. The company leverages its strong academic background and extensive experience in GPCR (G-protein-coupled receptor) drug discovery and development to create innovative therapies.
Caldan Therapeutics primarily targets the healthcare market, specifically aiming to serve patients suffering from metabolic and inflammatory diseases. Their clients include pharmaceutical companies, healthcare providers, and potentially patients who benefit from their novel treatments.
The company operates in the biotech and pharmaceutical industry, focusing on the discovery and development of drugs that activate free fatty acid receptors. These receptors are crucial because they play a significant role in the physiology of Type 2 Diabetes and other metabolic disorders. By targeting these receptors, Caldan Therapeutics aims to develop effective treatments that can manage or potentially cure these conditions.
Caldan's business model revolves around research and development (R&D). They invest heavily in scientific research to discover new drug candidates, which they then develop into marketable therapies. The company makes money through partnerships with larger pharmaceutical companies, licensing their drug candidates, and potentially through direct sales of their developed therapies once they receive regulatory approval.
In summary, Caldan Therapeutics is a biotech startup dedicated to creating new treatments for metabolic and inflammatory diseases. They combine academic expertise with practical experience in drug discovery, focusing on free fatty acid receptors to develop innovative therapies. Their business model is centered on R&D, partnerships, and licensing, aiming to bring new, effective treatments to the market.
Keywords: biotech, metabolic diseases, Type 2 Diabetes, NASH, inflammatory diseases, GPCR, drug discovery, free fatty acid receptors, R&D, pharmaceutical partnerships.